Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences
  • Register
  • Login

Urology Journal

  • Home
  • Instant Online
    • Instant 2023
    • Instant 2022
    • Instant 2021
    • Instant 2020
  • Current
  • Archives
  • Announcements
  • Submissions
  • Author Guidelines
  • About
    • About the Journal
    • Privacy Statement
    • Contact
Advanced Search
  1. Home
  2. Archives
  3. Vol. 19 No. 04 (2022): July-August 2022
  4. ORIGINAL PAPER(UROLOGICAL ONCOLOGY)

ISSN: 1735-1308

July-August 2022
Vol. 19 No. 04 (2022)

Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette–Guérin and the Relationship with the CUETO Scoring Model Significance of the NLR with CUETO model

  • Jae-Wook Chung
  • Jin Woo Kim
  • Eun Hye Lee
  • So Young Chun
  • Dong Jin Park
  • Kyeong Hyeon Byeon
  • Seock Hwan Choi
  • Jun Nyung Lee
  • Bum Soo Kim
  • Hyun Tae Kim
  • Eun Sang Yoo
  • Tae Gyun Kwon
  • Yun-Sok Ha
  • Tae-Hwan Kim

Urology Journal, Vol. 19 No. 04 (2022), , Page 281-288
https://doi.org/10.22037/uj.v18i.6765 Published 16 October 2021

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Purpose: In this study, we evaluated the predictability of a modified Club Urológico Español de Tratamiento Oncológico (CUETO) scoring model and preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle invasive bladder cancer (NMIBC).


Materials and Methods: From August 2005 to May 2016, a total of 281 patients received intravesical bacillus Calmette–Guérin therapy after transurethral resection of a bladder tumor. The pathologic stage of all patients was Ta or T1. Of 281 patients, 84 (29.9%) experienced recurrence and 14 (5.0%) developed progression. The mean follow-up period was 46 months. The cut-off value for NLRs was 2.29.


Results: One hundred-eight patients (38.4%) displayed a high NLR (> 2.29). In Kaplan–Meier curve analysis, a high NLR was associated with lower recurrence-free survival (RFS) (P < .001) and progression-free survival (PFS) (P = .002). CUETO scores were associated with RFS (P < .001), but not with PFS (P = .423). A combination of NLRs and the CUETO risk model correlated with RFS (P < .001) and PFS (P = .002). In multivariate analysis, female gender, concomitant carcinoma in situ (CIS), tumor number >3, recurrent tumors, and a high NLR were independent factors predicting recurrence (all P < .05). Concomitant CIS, recurrent tumors, and a high NLR were independent factors for predicting progression (all P < .05).


Conclusion: In patients with NMIBC, an NLR >2.29 was identified as a significant factor for predicting tumor recurrence and progression. Inclusion of preoperative NLR enhanced the accuracy of the CUETO model to predict disease progression.

Keywords:
  • Neutrophil-to-lymphocyte ratio; Bacillus Calmette–Guérin; Club Urológico Español de Tratamiento Oncológico risk model; Survival
  • 6765/pdf

How to Cite

Chung, J.-W., Kim, J. W., Lee, E. H., Chun , S. Y., Park, D. J., Byeon, K. H., Choi, S. H., Lee, J. N., Kim, B. S., Kim, H. T., Yoo, E. S., Kwon, T. G., Ha, Y.-S., & Kim, T.-H. (2021). Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette–Guérin and the Relationship with the CUETO Scoring Model: Significance of the NLR with CUETO model. Urology Journal, 19(04), 281-288. https://doi.org/10.22037/uj.v18i.6765
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
2. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639-53.
3. Babjuk M, Bohle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447-61.
4. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247-56.
5. Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol. 2016;69:60-9.
6. Hidas G, Pode D, Shapiro A, et al. The natural history of secondary muscle-invasive bladder cancer. BMC Urol. 2013;13:23.
7. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195-203.
8. Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol. 2018;18:90.
9. Lee BS, Lee SH, Son JH, et al. Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother. 2016;65:141-50.
10. Viers BR, Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urologic Oncology-Seminars and Original Investigations. 2014;32:1277-84.
11. Ceylan C, Doluoglu OG, Keles I, et al. Importance of the neutrophil-to-lymphocyte ratio in muscle-invasive and non-muscle invasive bladder tumors. Urologia. 2014;81:120-4.
12. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005;13:143-53.
13. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am. 2003;30:765-76.
14. Choi SY, Ryu JH, Chang IH, et al. Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models. Korean J Urol. 2014;55:643-9.
15. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. European Urology. 2006;49:466-77.
16. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205-9.
17. Mano R, Baniel J, Shoshany O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urologic Oncology-Seminars and Original Investigations. 2015;33.
18. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288-95.
19. Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH. The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy. Br J Cancer. 2015;112:461-7.
20. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23:31-9.
21. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44.
22. Aydin M, Bitkin A, Kadihasanoglu M, et al. Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. Actas Urol Esp. 2019;43:503-8.
23. Viers BR, Boorjian SA, Frank I, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. European Urology. 2014;66:1157-64.
24. Can C, Baseskioglu B, Yilmaz M, Colak E, Ozen A, Yenilmez A. Pretreatment Parameters Obtained from Peripheral Blood Sample Predicts Invasiveness of Bladder Carcinoma. Urologia Internationalis. 2012;89:468-72.
25. Potretzke A, Hillman L, Wong K, et al. NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder. Urologic Oncology-Seminars and Original Investigations. 2014;32:631-6.
26. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK. Preoperative Neutrophil/Lymphocyte Ratio Predicts Overall Survival and Extravesical Disease in Patients Undergoing Radical Cystectomy. Journal of Endourology. 2013;27:1046-50.
27. Favilla V, Castelli T, Urzi D, et al. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study. Int Braz J Urol. 2016;42:685-93.
28. Albayrak S, Zengin K, Tanik S, et al. Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? Kaohsiung Journal of Medical Sciences. 2016;32:327-33.
29. Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer? International Braz J Urol. 2019;45:315-24.
30. Marchioni M, Primiceri G, Ingrosso M, et al. The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review. Clinical Genitourinary Cancer. 2016;14:473-84.
  • Abstract Viewed: 0 times
  • 6765/pdf Downloaded: 0 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

In case of persistent problems in registration, primary uploading of a submission or uploading of a revision, please send us the submission files on the journal email at:

urologyjournal@sbmu.ac.ir

and please attach the screenshot of the error or problem you encountered in uploading.

 

Make a Submission

          Journal Research in Urology

Information
  • For Readers
  • For Authors
Keywords
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact
The template of this website is designed by Sinaweb